Thursday, November 29, 2012
• Nymox Pharmaceutical Corp., of Hasbrouck Heights, N.J., said it completed patient enrollment in its pivotal Phase III NX02-0017 study testing NX-1207 in benign prostatic hyperplasia. Top-line results are expected in late 2013.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.